Takeda yanks established drug on efficacy questions

Takeda Pharmaceutical will voluntarily recall Dasen, a 40-year-old anti-inflammatory drug touted as effective for a variety of conditions ranging from chronic bronchitis to sprained ankles, because recent tests have cast doubt on its efficacy. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.